{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T06:03:15Z","timestamp":1792821795180,"version":"4.5.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515012980"],"award-info":[{"award-number":["2024A1515012980"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2025B1515020081"],"award-info":[{"award-number":["2025B1515020081"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024T171070"],"award-info":[{"award-number":["2024T171070"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2023M744015"],"award-info":[{"award-number":["2023M744015"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["CKS-SYSUCC-2023002"],"award-info":[{"award-number":["CKS-SYSUCC-2023002"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["YTP-SYSUCC-0018"],"award-info":[{"award-number":["YTP-SYSUCC-0018"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018573","name":"Sun Yat-sen University Cancer Center","doi-asserted-by":"publisher","award":["CIRP-SYSUCC-0004"],"award-info":[{"award-number":["CIRP-SYSUCC-0004"]}],"id":[{"id":"10.13039\/501100018573","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82321003"],"award-info":[{"award-number":["82321003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173128"],"award-info":[{"award-number":["82173128"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["8240101755"],"award-info":[{"award-number":["8240101755"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018537","name":"National Science and Technology Major Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018537","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018904","name":"Beijing Xisike Clinical Oncology Research Foundation","doi-asserted-by":"publisher","award":["Y-QL202202-0089"],"award-info":[{"award-number":["Y-QL202202-0089"]}],"id":[{"id":"10.13039\/100018904","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2023ZD0501600"],"award-info":[{"award-number":["2023ZD0501600"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005153","name":"National Science Fund for Distinguished Young Scholars","doi-asserted-by":"publisher","award":["82425048"],"award-info":[{"award-number":["82425048"]}],"id":[{"id":"10.13039\/501100005153","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-Sen University","doi-asserted-by":"publisher","award":["84000-31630002"],"award-info":[{"award-number":["84000-31630002"]}],"id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.annonc.2026.01.005","type":"journal-article","created":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:21:57Z","timestamp":1768926117000},"page":"986-998","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-2136","authenticated-orcid":false,"given":"Y.X.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.K.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.H.","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7668-9674","authenticated-orcid":false,"given":"F.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongming","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shundong","family":"Cang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junye","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhendong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanhui","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meili","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Conghua","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canhong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunyu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daojun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhitu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rixin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liqun","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wangjun","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Xu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiyuan","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanru","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qichun","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.annonc.2026.01.005_bib1","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41571-023-00757-y","article-title":"Improving outcomes in patients with oesophageal cancer","volume":"20","author":"Shah","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"issue":"10466","key":"10.1016\/j.annonc.2026.01.005_bib2","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1016\/S0140-6736(24)02226-8","article-title":"Oesophageal cancer","volume":"404","author":"Yang","year":"2024","journal-title":"Lancet"},{"issue":"10302","key":"10.1016\/j.annonc.2026.01.005_bib3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study","volume":"398","author":"Sun","year":"2021","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.005_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ccell.2022.02.007","article-title":"Toripalimab plus chemotherapy in treatment-naive, advanced esophageal squamous cell carcinoma (JUPITER-06): a multi-center phase 3 trial","volume":"40","author":"Wang","year":"2022","journal-title":"Cancer Cell"},{"issue":"10","key":"10.1016\/j.annonc.2026.01.005_bib5","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1001\/jama.2021.12836","article-title":"Effect of camrelizumab vs placebo added to chemotherapy on survival and progression-free survival in patients with advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st randomized clinical trial","volume":"326","author":"Luo","year":"2021","journal-title":"JAMA"},{"issue":"9","key":"10.1016\/j.annonc.2026.01.005_bib6","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.medj.2024.05.008","article-title":"Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: the ESCORT-1st trial","volume":"5","author":"He","year":"2024","journal-title":"Med"},{"issue":"9","key":"10.1016\/j.annonc.2026.01.005_bib7","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1200\/JCO.22.01490","article-title":"Clinical benefit of first-line programmed death-1 antibody plus chemotherapy in low programmed cell death ligand 1-expressing esophageal squamous cell carcinoma: a post hoc analysis of JUPITER-06 and meta-analysis","volume":"41","author":"Wu","year":"2023","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.005_bib8","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.ccell.2023.03.016","article-title":"An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma","volume":"41","author":"Chen","year":"2023","journal-title":"Cancer Cell"},{"issue":"6","key":"10.1016\/j.annonc.2026.01.005_bib9","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.annonc.2026.01.005_bib10","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.annonc.2024.03.007","article-title":"Tumor mutational burden for the prediction of PD-(L)1 blockade efficacy in cancer: challenges and opportunities","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.005_bib11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jtho.2022.09.217","article-title":"Tislelizumab versus docetaxel in patients with previously treated advanced NSCLC (RATIONALE-303): a phase 3, open-label, randomized controlled trial","volume":"18","author":"Zhou","year":"2023","journal-title":"J Thorac Oncol"},{"issue":"16","key":"10.1016\/j.annonc.2026.01.005_bib12","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO-24-01818","article-title":"NOTCH1 mutation and survival analysis of tislelizumab in advanced or metastatic esophageal squamous cell carcinoma: a biomarker analysis from the randomized, phase III, RATIONALE-302 trial","volume":"43","author":"Lu","year":"2025","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.005_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.ccell.2022.12.004","article-title":"Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.005_bib14","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1016\/j.ccell.2023.09.011","article-title":"Progenitor-like exhausted SPRY1(+)CD8(+) T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma","volume":"41","author":"Liu","year":"2023","journal-title":"Cancer Cell"},{"issue":"7636","key":"10.1016\/j.annonc.2026.01.005_bib15","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/nature20805","article-title":"Integrated genomic characterization of oesophageal carcinoma","volume":"541","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.005_bib16","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/s41588-018-0331-5","article-title":"The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic","volume":"51","author":"Frankell","year":"2019","journal-title":"Nat Genet"},{"issue":"10","key":"10.1016\/j.annonc.2026.01.005_bib17","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.annonc.2022.07.003","article-title":"Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Obermannova","year":"2022","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.005_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104134","article-title":"ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma","volume":"10","author":"Obermannova","year":"2025","journal-title":"ESMO Open"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.005_bib19","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa2111380","article-title":"Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma","volume":"386","author":"Doki","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.005_bib20","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S1470-2045(23)00108-0","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.annonc.2026.01.005_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105854","article-title":"Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study","volume":"10","author":"Metges","year":"2025","journal-title":"ESMO Open"},{"issue":"9","key":"10.1016\/j.annonc.2026.01.005_bib22","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.7235","article-title":"Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648): 29-month follow-up from a randomized, open-label, phase III trial","volume":"13","author":"Kato","year":"2024","journal-title":"Cancer Med"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.005_bib23","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1007\/s12325-025-03115-9","article-title":"First-line tislelizumab plus chemotherapy for esophageal squamous cell carcinoma with programmed death-ligand 1 expression >\/= 1%: a retrospective analysis of RATIONALE-306","volume":"42","author":"Xu","year":"2025","journal-title":"Adv Ther"},{"issue":"10294","key":"10.1016\/j.annonc.2026.01.005_bib24","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.005_bib25","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaoncol.2022.5816","article-title":"Effectiveness of immune checkpoint inhibitors in patients with advanced esophageal squamous cell carcinoma: a meta-analysis including low PD-L1 subgroups","volume":"9","author":"Yap","year":"2023","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.005_bib26","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1158\/1078-0432.CCR-20-3054","article-title":"Tumor mutational burden as a predictor of immunotherapy response: is more always Better?","volume":"27","author":"Strickler","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.annonc.2026.01.005_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","article-title":"The challenges of tumor mutational burden as an immunotherapy biomarker","volume":"39","author":"Jardim","year":"2021","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.005_bib28","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s43018-019-0008-8","article-title":"Multimodal genomic features predict outcome of immune checkpoint blockade in non-small-cell lung cancer","volume":"1","author":"Anagnostou","year":"2020","journal-title":"Nat Cancer"},{"issue":"7","key":"10.1016\/j.annonc.2026.01.005_bib29","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1016\/j.annonc.2020.04.004","article-title":"HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients","volume":"31","author":"Shim","year":"2020","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.005_bib30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41389-020-00296-6","article-title":"Emerging role of SWI\/SNF complex deficiency as a target of immune checkpoint blockade in human cancers","volume":"10","author":"Zhou","year":"2021","journal-title":"Oncogenesis"},{"issue":"13","key":"10.1016\/j.annonc.2026.01.005_bib31","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.cell.2024.04.025","article-title":"ARID1A suppresses R-loop-mediated STING-type I interferon pathway activation of anti-tumor immunity","volume":"187","author":"Maxwell","year":"2024","journal-title":"Cell"},{"issue":"6377","key":"10.1016\/j.annonc.2026.01.005_bib32","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1126\/science.aan5951","article-title":"Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma","volume":"359","author":"Miao","year":"2018","journal-title":"Science"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.005_bib33","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1158\/2326-6066.CIR-22-0813","article-title":"SWI\/SNF complex genomic alterations as a predictive biomarker for response to immune checkpoint inhibitors in multiple cancers","volume":"11","author":"Wang","year":"2023","journal-title":"Cancer Immunol Res"},{"issue":"7893","key":"10.1016\/j.annonc.2026.01.005_bib34","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.annonc.2026.01.005_bib35","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41573-024-00978-5","article-title":"Chromatin remodellers as therapeutic targets","volume":"23","author":"Malone","year":"2024","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.005_bib36","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s13045-024-01563-4","article-title":"Wnt\/beta-catenin signaling pathway in carcinogenesis and cancer therapy","volume":"17","author":"Song","year":"2024","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.005_bib37","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40364-021-00323-7","article-title":"The Wnt signaling pathway in tumorigenesis, pharmacological targets, and drug development for cancer therapy","volume":"9","author":"Wang","year":"2021","journal-title":"Biomark Res"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.005_bib38","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12943-025-02306-w","article-title":"Wnt signaling in cancer: from biomarkers to targeted therapies and clinical translation","volume":"24","author":"Tufail","year":"2025","journal-title":"Mol Cancer"},{"key":"10.1016\/j.annonc.2026.01.005_bib39","article-title":"CDKN2A deletion in melanoma excludes T cell infiltration by repressing chemokine expression in a cell cycle-dependent manner","volume":"11","author":"Zhu","year":"2021","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.annonc.2026.01.005_bib40","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.it.2020.07.010","article-title":"Cell cycle regulation meets tumor immunosuppression","volume":"41","author":"Li","year":"2020","journal-title":"Trends Immunol"},{"issue":"65","key":"10.1016\/j.annonc.2026.01.005_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abc6424","article-title":"Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape","volume":"6","author":"Takeuchi","year":"2021","journal-title":"Sci Immunol"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.005_bib42","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13045-017-0471-6","article-title":"Wnt\/beta-catenin pathway: modulating anticancer immune response","volume":"10","author":"Pai","year":"2017","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10.1016\/j.annonc.2026.01.005_bib43","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/s41577-020-0300-y","article-title":"Immunomodulation by anticancer cell cycle inhibitors","volume":"20","author":"Petroni","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"7668","key":"10.1016\/j.annonc.2026.01.005_bib44","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/nature23465","article-title":"CDK4\/6 inhibition triggers anti-tumour immunity","volume":"548","author":"Goel","year":"2017","journal-title":"Nature"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2026.01.005_bib45","article-title":"A phase I dose-escalation study to evaluate safety and feasibility of neoadjuvant camrelizumab with palbociclib for the treatment of resectable esophageal squamous cell carcinoma (ESCC)","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2026.01.005_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175628","article-title":"Novel PORCN inhibitor WHN-88 targets Wnt\/beta-catenin pathway and prevents the growth of Wnt-driven cancers","volume":"945","author":"Yang","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.annonc.2026.01.005_bib47","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.bbadis.2017.12.001","article-title":"Inhibition of canonical WNT signaling pathway by beta-catenin\/CBP inhibitor ICG-001 ameliorates liver fibrosis in vivo through suppression of stromal CXCL12","volume":"1864","author":"Akcora","year":"2018","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"issue":"6","key":"10.1016\/j.annonc.2026.01.005_bib48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2174\/1568009615666150506093643","article-title":"CBP-dependent Wnt\/beta-catenin signaling is crucial in regulation of MDR1 transcription","volume":"15","author":"Xia","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.005_bib49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s13045-020-00990-3","article-title":"Targeting the Wnt\/beta-catenin signaling pathway in cancer","volume":"13","author":"Zhang","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2026.01.005_bib50","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2020.10.031","article-title":"Manipulating the Wnt\/beta-catenin signaling pathway to promote anti-tumor immune infiltration into the TME to sensitize ovarian cancer to ICB therapy","volume":"160","author":"Wall","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.annonc.2026.01.005_bib51","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-025-03575-0","article-title":"Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial","volume":"31","author":"Shitara","year":"2025","journal-title":"Nat Med"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000141?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753426000141?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:46:29Z","timestamp":1782315989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753426000141"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0923753426000141"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2026.01.005","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Final overall survival analysis and exploratory biomarker study from JUPITER-06: a randomized phase III trial of toripalimab plus chemotherapy in advanced esophageal squamous-cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2026.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society for Medical Oncology. Published by Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}